Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for POCD in elderly patients
NCT02275182Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Countries
- 1
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Modality
- Small Molecules
- Drugs
- dexmedetomidine
- Conditions
- Post-operative cognitive dysfunction (POCD)postoperative delirium (POD)
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in Post-operative cognitive dysfunction (POCD) and postoperative delirium (POD), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Incidence of postoperative cognition dysfunction at 7 days. Started Oct 2014; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Elderly patients (65-90 years) undergoing elective surgery (abdomen, orthopedics, urology) under general anesthesia with ASA II-III and anticipated surgery time of 2-6 hours. Excludes patients with dementia (MMSE < 20), mental disease, or bradycardia.
04
Endpoints
Primary
Incidence of postoperative cognition dysfunction
Beyond the preview
Go deeper on NCT02275182.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275182.